Xilio Therapeutics, Inc. Cash Flow Statement
XLO|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Xilio Therapeutics, Inc. used $18M in operating cash flow and negative free cash flow of $18M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$58.2M | -$76.4M |
| Depreciation & Amortization | $1.6M | $1.9M |
| Operating Cash Flow | -$18.4M | -$68.6M |
| Capital Expenditures | $36.0K | $486.0K |
| Free Cash Flow | -$18.4M | -$69.1M |
| FCF Margin | -290.3% | -1089.3% |